Lantheus Holdings, Inc. (LNTH)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$100.19+0.23%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $6.5B
- P/E (trailing)
- 24.3
- Forward P/E
- 15.7
- 52-week range
- $49.67 – $111.86
- 52-week change
- +92.82%
- EPS (trailing)
- $4.13
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $1.5B (+0.50%)
- Net income
- $234M
- Operating margin
- 20.2%
- Diluted EPS
- $3.41
From the company’s annual report on SEC EDGAR.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Headquarters: Bedford, United States · 1,193 employees · lantheus.com